8. BIBLIOGRAPHY


Jans et al. USOO575958OA, Compositions containing micronized Nebivolol.


Sahitya, Krishnamoorthy, and Muthukumaran. "Available through Online Review Article www.ijptonline.com Importance of preformulation studies in designing formulations for sustained release dosage forms."


ICH harmonized tripartite guideline, stability testing of new drug substances and products, Q1A(R2)


http://www.chemicalbook.com/ChemicalProductProperty_EN_CB9245093.htm (accessed on 3 July 2010)


Anusha, "development and evaluation of drotaverine taste masked tablets with improved dissolution efficiency using solid dispersion technique."

Use of drugs for acid related disorders: Rosaida, et al.


Khatri, Deepak "Studies on stability indicating assay methods and impurity profiling of active pharmaceutical drugs." (2013).

Kumar, Saurabh, Pravin Gupta, and Rahul Dev. "Formulation and Evaluation of Immediate Release Tablet of Telmisartan."


Vijayaraj, Gandhimathi, and Sarathkumar. "Innovative Drug Discovery."


Nevanac, Alcon research, inc., Chemistry review(s), application number 21-862, centre for drug evaluation and research


www.fda.gov/ohrms/dockets/ac/99/slides/3558s1i/sld016.htm (accessed on 15 Oct 2011)

http://www.chemicalbook.com/ChemicalProductProperty_EN_CB3191433.htm

McDonald, Marguerite et al. "Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis." Ophthalmology 116.9 (2009): 1615-1623.


Schlech, Barry, and Joseph Blondeau. "Future of ophthalmic anti-infective therapy and the role of moxifloxacin ophthalmic solution 0.5% (VIGAMOX®)." Survey of ophthalmology 50.6 (2005): S64-S67.

http://tsrlink.com/resources/services, MXP BCS classification details (accessed on 10 Oct 2010)

British Pharmacopeia Appendix XVI A: sterility and sub chapter IV P: Guidelines for sterility testing)